Introduction
obesity, NASH, type 2 diabetes, non-alcoholic steatohepatitis
OBESITY, NON-ALCOHOLIC STEATOHEPATITIS, TYPE 2 DIABETES
Glucagon-like peptide-1 receptor (GLP-1R) agonists, such as liraglutide and semaglutide, have been developed for the treatment of both type 2 diabetes and obesity. These therapies have produced placebo-corrected bodyweight decreases of up to 5.4% (liraglutide 3 mg) [In addition to the glucose-lowering effects associated with GLP-1R agonism, GCGR agonism, via receptors in the liver, may lead to increased energy expenditure [The efficacy of GCGR/GLP-1R dual agonism has been demonstrated by oxyntomodulin, an endogenous proglucagon derivative [Survodutide (BI 456906) is a novel subcutaneous GCGR/GLP-1R dual agonist in development for the treatment of people with type 2 diabetes, obesity and non-alcoholic steatohepatitis (NASH). Addition of a C18 fatty acid into the acylated peptide, as a half-life-extending principle, allows for weekly administration of survodutide [Here we report the results of a Phase II study (ClinicalTrials.gov NCT04153929) assessing the effects on HbA